| Methods |
DURATION OF INTERVENTION:
6 months
DURATION OF FOLLOW‐UP:
6 months
RUN‐IN PERIOD:
none
LANGUAGE OF PUBLICATION:
English |
| Participants |
WHO PARTCIPATED:
Koreans with type 2 diabetes mellitus who showed poor glycaemic control with glimepiride
INCLUSION CRITERIA:
aged 20‐70 years; secondary treatment failure (HbA1c > 8% on glimepiride 4 mg/day or equivalent dose of other sulfonylureas)
EXCLUSION CRITERIA:
no other severe illnesses including liver failure, renal failure, heart failure
DIAGNOSTIC CRITERIA:
not stated
CO‐MORBIDITIES:
retinopathy ‐
I: 3/14, C: 3/13
proteinuria ‐
I: 2/14, C: 3/13
coronary heart disease ‐
I: 2/14, C: 2/13
CO‐MEDICATIONS
lipid‐lowering agents ‐
I: 5/14, C: 3/13 |
| Interventions |
NUMBER OF STUDY CENTRES:
1
COUNTRY/ LOCATION:
Korea
SETTING:
diabetes clinic of the Seoul National University Hospital
INTERVENTION (DOSE/DAY):
rosiglitazone 4 mg/day + glimepiride 4 mg/day
CONTROL (DOSE/DAY):
metformin 1000 mg/day + glimepiride 4 mg/day
TREATMENT BEFORE STUDY:
glimepiride 4 mg/day or equivalent dose of other sulfonylureas
TITRATION PERIOD:
none |
| Outcomes |
PRIMARY OUTCOMES:
not stated
(resistin)
SECONDARY OUTCOMES:
(not stated)
adiponectin, FPG, lipids, HbA1c, plasma insulin, plasma C‐peptide |
| Notes |
AIM OF STUDY:
to see whether improving insulin resistance can modulate circulating resistin levels, the effects of two different insulin sensitizers, rosiglitazone and metformin, on plasma resistin concentrations in Korean participants with type 2 diabetes mellitus were investigated |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
